A first U.S. clinical trial of psilocybin-assisted therapy for veterans with treatment-resistant PTSD found the protocol to be safe, with no serious adverse events or increase in suicidal ideation.

Funding and collaboration details note support from Ohio State University entities and CPDRE, with authors from CPDRE and Ohio State.

Researchers note previous evidence from other contexts and express hope for funding to support larger, controlled studies.

The study frames psilocybin as a pharmacological catalyst that amplifies deep psychotherapeutic processing during integration, contributing to durable breakthroughs beyond the drug effect alone.

At one-month follow-up, nine of twelve participants no longer met PTSD criteria, with the average symptom severity score dropping by 27.5 points and suicidal ideation falling to 75% reporting no thoughts.

The treatment combined eight hours of psychotherapy, two psilocybin dosing sessions (15 mg then 25 mg, two to three weeks apart), and six to eight hours of integrative therapy afterward, over about 11 weeks.

Participants reported the therapy as a catalyst that enables deeper psychotherapeutic work during integration, suggesting the drug facilitates processing beyond the dosing sessions.

Safety signals were favorable, with only mild post-dosing headaches reported as the most common side effect.

Researchers emphasize the essential role of psychotherapy and view the drug as a facilitator of deeper therapeutic work, not a standalone cure.

While results are promising, the open-label design and lack of a control group mean larger, randomized trials are needed to validate efficacy and explore long-term outcomes.

Plans are in place for a larger randomized, double-blind, placebo-controlled trial to assess durability up to six months, biomarkers, sleep, and related symptoms like substance use.

The trial unfolds amid U.S. policy shifts: psilocybin remains a controlled substance, but there is momentum to speed reviews and funding for psychedelic therapies.